Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-11-06 | 2025-05-21 | 209286 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-04-24 | 2019-06-21 | 82337 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-01-15 | 2019-02-21 | 72363 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-08-23 | 2023-11-06 | 202824 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-05-19 | 2023-07-21 | 192800 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-07-27 | 2025-05-21 | 200177 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-06-05 | 2019-06-21 | 85619 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-05-19 | 2023-06-23 | 192818 |
| APO-TAMSULOSIN CR | 0.4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-05-15 | 2019-06-24 | 84159 |
| APO-TELMISARTAN | 40MG | TABLET | Resolved | 2017-06-06 | 2017-10-03 | 12080 |
| APO-TELMISARTAN | 40MG | TABLET | Resolved | 2018-07-11 | 2018-07-11 | 55290 |
| APO-TELMISARTAN | 80MG | TABLET | Resolved | 2017-05-24 | 2017-10-03 | 11047 |
| APO-TELMISARTAN | 40MG | TABLET | Resolved | 2018-07-15 | 2018-09-12 | 55794 |
| APO-TELMISARTAN | 80MG | TABLET | Resolved | 2018-07-15 | 2018-09-12 | 55798 |
| APO-TELMISARTAN/HCTZ | 25MG 80MG | TABLET | Actual shortage | 2017-05-24 | 2018-12-20 | 11050 |
| APO-TELMISARTAN/HCTZ | 12.5MG 80MG | TABLET | Resolved | 2017-05-04 | 2018-09-12 | 8922 |
| APO-TELMISARTAN/HCTZ | 12.5MG 80MG | TABLET | Resolved | 2017-04-11 | 2018-09-12 | 6524 |
| APO-TELMISARTAN/HCTZ | 12.5MG 80MG | TABLET | Resolved | 2017-03-13 | 2017-03-31 | 748 |
| APO-TENOFOVIR | 300MG | TABLET | Resolved | 2020-09-30 | 2020-11-16 | 125338 |
| APO-TENOFOVIR | 300MG | TABLET | Resolved | 2018-07-25 | 2018-09-04 | 56538 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
| APO-FENTANYL MATRIX | 75MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60497 |
| APO-FENTANYL MATRIX | 100MCG | PATCH | Discontinued | 2018-02-23 | 2018-12-28 | 40741 |
| APO-FENTANYL MATRIX | 25MCG | PATCH | Discontinued | 2018-09-07 | 2018-09-15 | 60489 |
| APO-FLUNISOLIDE NASAL SPRAY | 0.25MG | METERED-DOSE PUMP | Discontinued | 2018-02-26 | 2018-02-26 | 40965 |
| APO-FLUVOXAMINE TABLETS | 50MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4716 |
| APO-FLUVOXAMINE TABLETS | 100MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4713 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2019-01-02 | 2019-01-02 | 70815 |
| APO-GAIN LIQ 20MG/ML | 20MG | SOLUTION | Discontinued | 2018-02-26 | 2018-02-26 | 40997 |
| APO-GEMFIBROZIL | 600MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4927 |
| APO-GEMFIBROZIL CAP 300MG USP | Discontinued | 2019-06-12 | 2019-06-12 | 86557 | ||
| APO-GEMFIBROZIL CAP 300MG USP | 300MG | CAPSULE | Discontinued | 2017-03-31 | 2018-12-07 | 4920 |
| APO-GLICLAZIDE | 80MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60512 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-HALOPERIDOL TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1084 |
| APO-HALOPERIDOL TAB 5MG | 5MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1087 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |